Drug discrimination in methamphetamine-trained monkeys: Agonist and antagonist effects of dopaminergic drugs

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 1163-1174

  Tidey, Jennifer W ^a,b   Bergman, Jack ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ALLYL 2,3,4,5 TETRAHYDRO 1 PHENYL 1H 3 BENZAZEPINE 7,8 DIOL; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 (4 HYDROXYPHENYL) 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; ATOMOXETINE; COCAINE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ECOPIPAM; EMONAPRIDE; FLUOXETINE; METHAMPHETAMINE; N (2 CHLORO 6 METHYLERGOLIN 8ALPHA YL)PIVALAMIDE; N (2,6 DIMETHYLERGOLIN 8ALPHA YL)PIVALAMIDE; NAXAGOLIDE; REMOXIPRIDE; VANOXERINE;

ARTICLE; BEHAVIOR; CATALEPSY; CLINICAL ARTICLE; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SQUIRREL MONKEY;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ADRENERGIC AGENTS; ANIMALS; BENZAZEPINES; CATALEPSY; DISCRIMINATION LEARNING; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; MALE; METHAMPHETAMINE; OXAZINES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SAIMIRI;

EID: 0031837755     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Ackerman JM, Johansen PA, Clark D and White FJ (1993) Electrophysiological effects of putative autoreceptor-selective dopamine agonists on A10 dopamine neurons. J Pharmacol Exp Ther 265:963-970.
2. 1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 273:309-314.
3. Andersen PJ (1989) The dopamine inhibitor, GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166:493-504.
4. 1 receptor efficacy. Eur J Pharmacol 188:335-347.
5. Ariens EJ (1983) Intrinsic activity: partial agonists and partial antagonists. J Cardiovasc Pharmacol 5:S8-S15.
6. Arnold EB, Molinoff PB and Rutledge CO (1977) The release of endogenous norepinephrine and dopamine from cerebral cortex by amphetamines. J Pharmacol Exp Ther 202:544-547.
7. 1 antagonists: comparison with other drugs and modification by haloperidol. J Pharmacol Exp Ther 245:471-478.
8. Bergman J, Madras BK, Johnson SE and Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates: III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251:150-155.
9. 2 antagonists. Behav Pharmacol 1:355-363.
10. 1 agonists, in Problems of Drug Dependence 1991, NIDA Research Monograph 119, pp 185-189, U. S. Government Printing Office, Washington, DC.
11. 2 receptor agonists on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther 273:40-48.
12. 1 receptor ligands: Drug interaction studies in squirrel monkey. J Pharmacol Exp Ther 276:942-950.
13. 2 receptor function in rats. J Pharmacol Exp Ther 266:585-592.
14. 2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology 103:50-55.
15. Casey D and Keepers GA (1988) Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia, in Psychopharmacology: Current Trends (Casey DE and Christensen AV) pp 74-93, Springer, New York.
16. 2, dopamine receptor agonists. 1. Atypical inhibition of d-amphetamine-induced locomotor hyperactivity and stereotypy. Psychopharmacology 105:381-392.
17. Coward DM, Dixon AK, Urwyler S, White TG, Enz A, Karobath M and Shearman G (1990) Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912. J Pharmacol Exp Ther 252:279-285.
18. De La Garza R and Johanson CE (1983) Disciminative stimulus properties of cocaine in the rhesus monkey. Pharmacol Biochem Behav 19:145-148.
19. Eshleman AJ, Henningsen RA, Neve KA and Jonowsky A (1994) Release of dopamine via the human transporter. Mol Pharmacol 45:312-316.
20. 2 dopamine receptor agonists in rats discriminating d-amphetamine from saline. Behav Pharmacol 3:609-619.
21. 2 dopamine receptor agonists on the d-amphetamine discriminative cue. Behav Pharmacol 1:110-111.
22. Gauvin DV and Young AM (1989) Evidence for perceptual masking of the discriminative morphine stimulus. Psychopharmacology 98:212-221.
23. 1 receptor agonists by squirrel monkeys. Psychopharmacology 125:97-104.
24. 3H]dopamine in rat brain tissue slices. Biochem Pharmacol 24:847-852.
25. 1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur J Pharmacol 246:39-44.
26. Johanson CE and Fischman MW (1989) The pharmacology of cocaine related to its abuse. Pharmacol Rev 41:3-52.
27. Kamien JB and Woolverton WL (1989) A pharmacological analysis of the discriminative stimulus properties of d-amphetamine in rhesus monkeys. J Pharmacol Exp Ther 248:938-946.
28. 1 dopamine receptor agonist, SKF 38393, on behavior maintained by cocaine injection in squirrel monkeys. Psychopharmacology 109:241-244.
29. 1 dopamine agonists on schedule-controlled behavior in the squirrel monkey. Behav Pharmacol 6:143-148.
30. Kebabian JW and Calne DB (1979) Multiple receptors for dopamine. Nature 277:93-96.
31. Kelleher RT and Morse WH (1968) Determinants of the specificity of behavioral effects of drugs. Ergebnisse Physiol 60:1-56.
32. Kleven MS, Anthony EW and Woolverton WL (1990) Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 254:312-317.
33. Koetzner L, Riley AL and Glowa JR (1996) Discriminative stimulus effects of dopaminergic agents in rhesus monkeys. Pharmacol Biochem Behav 54:517-523.
34. 2 guanine-nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities. Mol Pharmacol 42:432-438.
35. Liebman J and Neale R (1980) Neuroleptic-induced acute dyskinesias in squirrel monkeys: Correlation with propensity to cause extrapyramidal side effects. Psychopharmacology 68:25-29.
36. 2 dopamine receptors in caudate-putamen of nonhuman primates (Macaca fascicularis). J Neurochem 51:934-943.
37. McKearney JW (1974) Effects of d-amphetamine, morphine and chlorpromazine on responding under fixed-interval schedules of food presentation or electric shock presentation. J Pharmacol Exp Ther 190:141-153.
38. Melia KF and Spealman RD (1991) Pharmacological characterization of the discriminative-stimulus effects of GBR 12909. J Pharmacol Exp Ther 258:626-632.
39. 1 dopamine receptor agonist. J Pharmacol Exp Ther 262:383-393.
40. 1 receptors depends on intrinsic activity. Neuropharmacology 31:177-183.
41. 2 agonists in squirrel monkeys. J Pharmacol Exp Ther 273:138-145.
42. Pulvirenti L, Smith D and Koob GF (1994) SDZ 208-911, an amino-ergoline with partial dopamine agonist properties, dose dependently increases cocaine self-administration in the rat. Psychopharmacology 113:518-520.
43. 2 agonist (+)-PHNO by dopamine antagonists in monkeys. J Pharmacol Exp Ther 265:1039-1046.
44. 1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys. J Pharmacol Exp Ther 267:765-775.
45. 1 receptor agonists in squirrel monkeys. Eur J Pharmacol 260:237-241.
46. 2 agonists in squirrel monkeys. Psychopharmacology 116:9-18.
47. Ruffolo RR Jr (1982) Important concepts of receptor theory. J Autonom Pharmacol 2:277-295.
48. Spealman RD (1985) Discriminative-stimulus effects of midazolam in squirrel monkeys: Comparison with other drugs and antagonism by Ro 15-1788. J Pharmacol Exp Ther 235:456-462.
49. Spealman RD (1990) Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers. Psychopharmacology 101:142-145.
50. Spealman RD (1993) Modification of behavioral effects of cocaine by serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology 112:93-99.
51. 2 partial agonists terguride, SDZ 208-911, and SDZ 208-912. Pharmacol Biochem Behav 51:661-665.
52. Spealman RD (1995b) Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 275:53-62.
53. Spealman RD, Bergman J, Madras BK and Melia KF (1991) Discriminative stimulus effects of cocaine in squirrel monkeys: involvement of dopamine receptor subtypes. J Pharmacol Exp Ther 258:945-953.
54. 1 agonists. Psychopharmacology 133:283-292.
55. Svensson K, Ekman A, Piercey MF, Hoffman WE, Lum JT and Carlsson A (1991) Effects of the partial dopamine agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. Naunyn-Schmiedeberg Arch Pharmacol 344:263-274.
56. Tallarida RJ and Murray RB (1986) Manual of Pharmacologic Calculations with Computer Programs, 2nd ed, Springer-Verlag, New York.
57. Vermeulen RJ, Johgenelen CAM, Langeveld CH, Wolters EC, Stoof JC and Drukarch B (1994) Dopamine D1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytes. Eur J Pharmacol Mol Pharmacol 269:121-125.
58. 1 receptor agonists in rhesus monkeys. J Pharmacol Exp Ther 275:1367-1374.
59. 1 agonists in monkeys. J Pharmacol Exp Ther 283:29-38.
60. Witkin JM, Nichols DE, Terry P and Katz JL (1991) Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J Pharmacol Exp Ther 257:706-711.
61. 2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav 24:531-535.
62. Woolverton WL, Goldberg LI and Ginos JZ (1984) Intravenous self-administration of dopamine receptor agonists by rhesus monkeys. J Pharmacol Exp Ther 230:678-683.
63. Woolverton WL and Johnson KM (1992) Neurobiology of cocaine abuse. Trends Pharmacol Sci 13:193-200.